Recent clinical trials have compared the use of different chemotherapeutic regimens as "immune induction therapies" to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reputed to be inducers of immunogenic cell death (ICD) appeared to be particularly efficient for this purpose. A trial published in Nature Medicine by Thibaudin et al. reveals the capacity of oxaliplatin-based chemotherapy to sensitize RAS-mutant unresectable metastatic colorectal cancer to ICIs blocking CTLA-4 and PD-L1.
Sarah Lévesque, Julie Le Naour, Federico Pietrocola, Juliette Paillet, Margerie Kremer, Francesca Castoldi, Elisa Elena Baracco, Yan Wang, Erika Vacchelli, Gautier Stoll, Ariane Jolly, Pierre de la Grange, Laurence Zitvogel, Guido Guido Kroemer, Jonathan Pol
Georgina V. Long, Grant A. McArthur, Shahneen Sandhu, Robyn P.M. Saw, Euan Walpole, Alexander M. Menzies, B. Mark Smithers, David Gyorki, Emilia Nan Tie, Julia Lai‐Kwon, Michael Rtshiladze, Lumine Na, J Bozzi, Tavis Read, Victoria Atkinson, George Au‐Yeung
Discussion(0)
No comments yet. Be the first to comment.